ARTICLE | Company News
BioMS, Eli Lilly deal
October 5, 2009 7:00 AM UTC
Lilly returned to BioMS all rights to dirucotide (formerly MBP8298), terminating a 2007 deal for exclusive, worldwide rights to the synthetic myelin basic protein (MBP) peptide to treat multiple scle...